← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	3,915	+250	+7%	$603B
2	2 Pfizer PFE $168B	3,004	+87	+3%	$99.6B
3	3 Amgen AMGN $236B	2,862	+32	+1%	$109B
4	4 McKesson MCK $117B	1,674	+125	+8%	$62.2B
5	5 Novo Nordisk NVO $173B	1,667	-120	-7%	$29.1B
6	6 Becton Dickinson BDX $53.1B	1,631	+52	+3%	$58.7B
7	7 Regeneron Pharmaceuticals REGN $82B	1,321	-71	-5%	$66.7B
8	8 AstraZeneca AZN $258B	1,221	-10	-0.8%	$33.7B
9	9 ResMed RMD $33.8B	872	+70	+9%	$20.7B
10	10 Conagra Brands CAG $6.87B	853	-20	-2%	$11.4B
11	11 West Pharmaceutical WST $27B	748	+18	+2%	$22.9B
12	12 Lamb Weston LW $7.53B	704	+17	+2%	$9.53B
13	13 DaVita DVA $12.1B	597	-4	-0.7%	$11B
14	14 Teva Pharmaceutical Industries Limited TEVA $48.5B	585	+41	+8%	$14.7B
15	15 BellRing Brands BRBR $1.05B	503	+53	+12%	$9.3B
16	16 Viking Therapeutics VKTX $3.4B	409	-13	-3%	$3.3B
17	17 DELISTED WK Kellogg Co KLG	400	+22	+6%	$1.46B
18	18 Hims & Hers Health HIMS $6.82B	395	+86	+28%	$3.98B
19	19 Embecta EMBC $366M	368	+1	+0.3%	$1.14B
20	20 Inspire Medical Systems INSP $2.02B	358	+12	+3%	$6.2B
21	21 Madrigal Pharmaceuticals MDGL $10.5B	283	+26	+10%	$7.08B
22	22 Amphastar Pharmaceuticals AMPH $1.11B	263	-16	-6%	$1.31B
23	23 Biohaven BHVN $1.67B	256	+2	+0.8%	$3.48B
24	24 Dr. Reddy's Laboratories RDY $10.8B	248	+20	+9%	$1.87B
25	25 MannKind Corp MNKD $1.01B	244	+13	+6%	$1.08B